Skeletal Muscle Performance Biomarkers for Functional Mobility

Abstract

Skeletal muscle performance is a cornerstone of functional mobility in both healthy individuals and patients with acute or chronic medical conditions. Recent advancements in the identification and validation of skeletal muscle performance biomarkers have transformed the evaluation, monitoring, and management of mobility impairments. This review synthesizes current evidence on key biomarkers, their pathophysiological significance, diagnostic utility, and clinical implications for improving functional outcomes. Emphasis is placed on the integration of molecular, imaging, and functional metrics aligned with guideline-based recommendations to optimize patient care.

Introduction

Functional mobility is essential for maintaining independence, quality of life, and overall health. Decline in skeletal muscle performance underlies a significant proportion of mobility limitations, particularly in aging populations and individuals with chronic diseases. The clinical assessment of muscle function has traditionally relied on physical performance tests; however, the emergence of precise biomarkers offers new opportunities for early detection, risk stratification, and tailored interventions. This article provides a comprehensive overview of skeletal muscle performance biomarkers relevant to functional mobility, focusing on their scientific basis, clinical relevance, and practical applications.

Epidemiology / Disease Burden

Mobility impairment affects up to 30% of individuals over the age of 65 and is associated with increased morbidity, mortality, and healthcare utilization. Sarcopenia, frailty, and chronic neuromuscular conditions remain primary contributors to the global burden of disability. The World Health Organization estimates that musculoskeletal disorders account for approximately 17% of years lived with disability worldwide. The identification of robust biomarkers for muscle performance is therefore critical to addressing this significant public health issue and guiding resource allocation for prevention and rehabilitation strategies.

Pathophysiology

Skeletal muscle performance depends on the intricate interplay of muscle mass, fiber composition, mitochondrial function, neuromuscular junction integrity, and systemic factors such as inflammation and hormonal regulation. Age-related changes, chronic diseases, and disuse induce atrophy, fiber-type shifts, mitochondrial dysfunction, and impaired protein synthesis. Key biomarkers such as creatine kinase, myostatin, and inflammatory cytokines reflect underlying molecular mechanisms that compromise muscle contractility and endurance. Imaging biomarkers, including muscle cross-sectional area and echo intensity measured by MRI or ultrasound, provide structural and compositional insights correlated with functional outcomes.

Risk Factors

Risk factors for impaired skeletal muscle performance encompass biological, lifestyle, and disease-related determinants. Advanced age, physical inactivity, malnutrition, chronic systemic inflammation, endocrine disturbances (e.g., hypogonadism, diabetes), and multimorbidity are established contributors. Genetic predispositions, such as polymorphisms in genes regulating muscle metabolism and repair, also modulate individual susceptibility. Recognition of these risk factors is essential for targeted screening and early intervention using biomarker-guided approaches.

Clinical Features

Clinically, reduced skeletal muscle performance manifests as decreased strength, endurance, and mobility. Patients may present with difficulty rising from a chair, reduced gait speed, impaired balance, and increased risk of falls. Objective measures such as handgrip strength, sit-to-stand time, and six-minute walk distance are commonly used functional tests. These assessments, when combined with biochemical and imaging biomarkers, enhance the accuracy of diagnosing and monitoring mobility disorders.

Diagnosis

The diagnostic evaluation of skeletal muscle performance integrates clinical assessment with laboratory and imaging biomarkers. Serum creatine kinase and lactate dehydrogenase can indicate muscle damage, while lower levels of insulin-like growth factor-1 (IGF-1) and elevated myostatin signal catabolic states. Advanced imaging modalities, including MRI and ultrasound, quantify muscle mass and quality. Functional biomarkers, such as electromyography and isokinetic dynamometry, assess neuromuscular activation and contractile capacity. Composite indices, like the Short Physical Performance Battery (SPPB), enhance diagnostic precision when used alongside molecular and imaging data.

Treatment & Management

Management of impaired skeletal muscle performance focuses on addressing underlying etiologies, optimizing nutrition, implementing resistance and aerobic exercise programs, and pharmacologic interventions where indicated. Biomarker monitoring enables personalized therapy by tracking response and adjusting interventions. Nutritional supplementation with protein, vitamin D, and essential amino acids supports muscle anabolism. In selected cases, anabolic agents, anti-inflammatory drugs, and hormonal therapies are employed under specialist supervision. Multidisciplinary rehabilitation, incorporating physiotherapy and occupational therapy, remains fundamental to restoring functional mobility.

Recent Advances / Emerging Therapies

Recent advances have expanded the spectrum of skeletal muscle performance biomarkers to include novel molecular markers such as circulating microRNAs, muscle-specific exosomes, and advanced imaging-derived metrics like muscle fat infiltration quantification. Gene editing techniques and regenerative therapies targeting satellite cells are being explored in preclinical and early clinical studies. Wearable sensor technology enables real-time, longitudinal monitoring of muscle function in ambulatory settings, facilitating remote patient management and early detection of decline.

Guideline Recommendations

Clinical guidelines from organizations such as the European Working Group on Sarcopenia in Older People (EWGSOP) and the American Geriatrics Society emphasize the integration of objective muscle performance biomarkers into routine assessment of older adults and at-risk populations. They recommend using a combination of functional, biochemical, and imaging markers to enhance diagnostic accuracy and guide individualized treatment plans. Regular assessment and risk stratification are advised for patients with chronic diseases and those undergoing major surgery or rehabilitation.

Conclusion

The identification and application of skeletal muscle performance biomarkers have revolutionized the assessment and management of functional mobility disorders. By combining molecular, imaging, and functional markers, clinicians can achieve earlier diagnosis, more precise risk stratification, and personalized interventions. Ongoing research into novel biomarkers and emerging technologies promises to further refine clinical practice and improve outcomes for individuals with impaired mobility. Integrating these advancements into multidisciplinary care pathways is essential to addressing the growing burden of mobility-related disability in aging and medically complex populations.